Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | GAA | P10253 | 2/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ATIC | P31939 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.54 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891805 | 0.89 | ALDH1A1 (0.72) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL4968417 | 0.87 | FFAR4 (0.71) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL10182996 | 0.86 | ALDH1A1 (0.69) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL6831222 | 0.86 | ALDH1A1 (0.74) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL4968283 | 0.84 | ALDH1A1 (1.00) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL6151524 | 0.83 | FFAR4 (0.78) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL5955952 | 0.82 | MAPT (0.55) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL461513 | 0.81 | ALDH1A1 (0.61) | ALDH1A1GAAMAPTLMNARECQL | |
| SCHEMBL8698789 | 0.81 | MAPT (0.54) | ALDH1A1GAAPOLBPKMMAPT | |
| SCHEMBL5429681 | 0.80 | SMN1; SMN2 (0.67) | ALDH1A1GAAPKMMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| EP-1820799-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1239852-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | Arrow Therapeutics Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001028537-A2 | BISSULFONAMIDE DERIVATIVES AS ENZYME INHIBITORS | ARROW THERAPEUTICS LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| EP-0547414-B1 | Process for the preparation of N-substituted nitro-p-phenylenediamines | HOECHST AG (DE) | 1996-03-20 | — | — | EP | disclosed |
| US-5414128-A | Dehydrofluorination for amination | CASSELLA AG (DE) | 1995-05-09 | — | — | US | disclosed |
| EP-0547414-A2 | Process for the preparation of N-substituted nitro-p-phenylenediamines | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-23 | — | — | EP | disclosed |
| US-5041143-A | N,N'-disubstituted nitro-para-phenylenediamines, and dyeing compositions containing the same | L'OREAL (FR) | 1991-08-20 | — | — | US | disclosed |
| US-4910341-A | Reacting chloroethyl chloroformate with 4-halo-3-nitroaniline in presence of a base; cyclization; alkaline hydrolysis | L'OREAL (FR) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | ALDH1A1 492/4885GAA 2281/4885POLB 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.